News
08-16-2018, 12:32 AM
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
More... (https://www.news-medical.net/news/20180816/Trial-shows-PARP-inhibitor-as-novel-treatment-option-for-patients-with-advanced-breast-cancers.aspx)
More... (https://www.news-medical.net/news/20180816/Trial-shows-PARP-inhibitor-as-novel-treatment-option-for-patients-with-advanced-breast-cancers.aspx)